company background image
MPH

Mediland PharmASX:MPH Stock Report

Market Cap

AU$21.9m

7D

1.4%

1Y

-30.0%

Updated

20 Oct, 2021

Data

Company Financials
MPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

MPH Overview

Mediland Pharm Limited, together with subsidiaries, engages in the retail sale of health, beauty, and wellness products in Australia and New Zealand.

Price History & Performance

Summary of all time highs, changes and price drops for Mediland Pharm
Historical stock prices
Current Share PriceAU$0.07
52 Week HighAU$0.043
52 Week LowAU$0.11
Beta0.53
1 Month Change20.69%
3 Month Change-2.78%
1 Year Change-30.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-66.67%

Recent News & Updates

Sep 15
Mediland Pharm (ASX:MPH) Is Carrying A Fair Bit Of Debt

Mediland Pharm (ASX:MPH) Is Carrying A Fair Bit Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

MPHAU Specialty RetailAU Market
7D1.4%1.9%1.7%
1Y-30.0%24.7%20.2%

Return vs Industry: MPH underperformed the Australian Specialty Retail industry which returned 24.7% over the past year.

Return vs Market: MPH underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is MPH's price volatile compared to industry and market?
MPH volatility
MPH Beta0.53
Industry Beta1.2
Market Beta1

Stable Share Price: Insufficient data to determine MPH's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine MPH's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aYesh Mudaliarhttps://www.medilandpharm.com.au

Mediland Pharm Limited, together with subsidiaries, engages in the retail sale of health, beauty, and wellness products in Australia and New Zealand. The company’s stores also offers luxury products, such as opal and pink diamond jewelry pieces, souvenirs and gifts, luxurious bedding and rugs. It operates through one direct store in Australia; one store in Auckland, New Zealand; six franchise shops in China; three WeChat accounts; and four e-commerce platforms.

Mediland Pharm Fundamentals Summary

How do Mediland Pharm's earnings and revenue compare to its market cap?
MPH fundamental statistics
Market CapAU$21.89m
Earnings (TTM)-AU$6.26m
Revenue (TTM)AU$1.16m

18.9x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MPH income statement (TTM)
RevenueAU$1.16m
Cost of RevenueAU$1.10m
Gross ProfitAU$55.68k
ExpensesAU$6.32m
Earnings-AU$6.26m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin4.81%
Net Profit Margin-541.20%
Debt/Equity Ratio83.0%

How did MPH perform over the long term?

See historical performance and comparison

Valuation

Is Mediland Pharm undervalued compared to its fair value and its price relative to the market?

7.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MPH is unprofitable, so we can't compare its PE Ratio to the Australian Specialty Retail industry average.

PE vs Market: MPH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MPH is overvalued based on its PB Ratio (7.2x) compared to the AU Specialty Retail industry average (3.9x).


Future Growth

How is Mediland Pharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

0.6%

Forecasted Retail industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mediland Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Mediland Pharm performed over the past 5 years?

-61.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MPH is currently unprofitable.

Growing Profit Margin: MPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MPH is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.

Accelerating Growth: Unable to compare MPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MPH is unprofitable, making it difficult to compare its past year earnings growth to the Specialty Retail industry (91.8%).


Return on Equity

High ROE: MPH has a negative Return on Equity (-207.45%), as it is currently unprofitable.


Financial Health

How is Mediland Pharm's financial position?


Financial Position Analysis

Short Term Liabilities: MPH's short term assets (A$3.9M) exceed its short term liabilities (A$2.6M).

Long Term Liabilities: MPH's short term assets (A$3.9M) do not cover its long term liabilities (A$4.2M).


Debt to Equity History and Analysis

Debt Level: MPH's debt to equity ratio (83%) is considered high.

Reducing Debt: Insufficient data to determine if MPH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MPH has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 24% each year.


Dividend

What is Mediland Pharm current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MPH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Yesh Mudaliar

3.17yrs

Tenure

AU$109,709

Compensation

Mr. Yeshween Mudaliar, also known as Yesh, is Managing Director and Director of Mediland Pharm Limited since August 27, 2018. Mr. Mudaliar is a professional hospitality executive with industry experience....


CEO Compensation Analysis

Compensation vs Market: Yesh's total compensation ($USD82.03K) is below average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Yesh's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MPH's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: MPH's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mediland Pharm Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Mediland Pharm Limited
  • Ticker: MPH
  • Exchange: ASX
  • Founded: 2002
  • Industry: Specialty Stores
  • Sector: Retail
  • Market Cap: AU$21.893m
  • Shares outstanding: 312.76m
  • Website: https://www.medilandpharm.com.au

Location

  • Mediland Pharm Limited
  • 18-40 Anderson Street
  • Parramatta
  • New South Wales
  • 2150
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 07:04
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.